ANKTIVA
(Anktiva)Phase 2Small molecule
ANKTIVA is one of 19 small molecule programs targeting COVID-19. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Singulair
AstraZenecaPreclinical
ANKTIVA
AAltor BioScience
Phase 2
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Conventional
PPopulation Health Research Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Apr 22, 2024
ANKTIVA
BLA BLA761336
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anktiva. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAltor BioScience